La vacunación de las mucosas puede estimular la inmunidad tanto...Leer más
Use of mRNA COVID-19 vaccines should be considered as the preferable option in the US rather than Johnson & Johnson’s (J&J) Janssen COVID-19 vaccine in women under the age of 50 years, according to one group of experts.
The group makes their recommendation in an editorial in JAMA published online April 30, accompanying a paper describing details of 12 case reports of cerebral venous sinus thrombosis (CVST) with thrombocytopenia following the J&J COVID-19 vaccine, also known as the Ad26.COV2.S vaccine.
The editorialists are Ruth A. Karron, MD, professor of international health at Johns Hopkins Bloomberg School of Public Health in Baltimore, Maryland; Nigel S. Key, MD, professor of hematology at University of North Carolina at Chapel Hill; and Joshua M. Sharfstein, MD, associate dean for public health practice at Johns Hopkins Bloomberg School of Public Health.
They note that after an initial pause following reports of thrombosis with thrombocytopenia syndrome (TTS) linked to the J&J vaccine, and on the recommendation of the Advisory Committee on Immunization Practices, the US has permitted the use of the J&J vaccine in all adults with information on the risk of TTS added to educational materials.
The editorialists point out that no cases of TTS have been confirmed following administration of more than 180 million doses of the mRNA vaccines in the US.
They say that while the J&J vaccine will still be needed for individuals with allergies to components of the mRNA vaccines and for those who live in remote locations where the cold chain for transport and storage of mRNA vaccines cannot be maintained, “US public health agencies and clinicians should consider recommending mRNA vaccines as safer options for those who may be at substantially higher risk for TTS after Ad26.COV2.S vaccination, currently women younger than 50 years.”
In the main JAMA paper, a group led by Isaac See, MD, Centers for Disease Control and Prevention (CDC) COVID-19 Response Team, report full details of 12 cases of CVST with thrombocytopenia following the J&J COVID-19 vaccine reported to the US Vaccine Adverse Event Reporting System (VAERS).
The 12 US case reports, three of which were fatal, show many similarities to cases described in Europe after the AstraZeneca vaccine.
The authors note that by April 12, approximately 7 million doses of the J&J vaccine had been given in the US. The 12 cases of CVST and thrombocytopenia following receipt of the vaccine were reported to VAERS between March 2 and April 21. All 12 cases were in white women, 11 of whom were under 50 years of age.
As of April 25, a further two cases have been confirmed and reported to VAERS; one in a man younger than 40 years, the other in a woman aged between 40 and 59 years.
In the 12 cases reported in detail, symptoms started between 6 and 15 days post vaccination.
At least 1 risk factor for CVST was identified in 7 patients (obesity in 6, hypothyroidism in 1, and use of combined oral contraceptives in 1). None of the patients was pregnant or within 12 weeks postpartum, had prior thrombosis, a personal or family history of thrombophilia, or documented prior exposure to heparin. In addition to CVST, seven patients had intracerebral hemorrhage and eight had non-CVST thromboses.
One patient reported a history of SARS-CoV-2 infection approximately 4 months prior to vaccination. Of the other 11 patients, four had negative serologic tests and seven were not tested.
All 12 patients were hospitalized and 10 were admitted to an intensive care unit (ICU). At the time of the last follow-up, three patients had died (all of whom had intraparenchymal hemorrhage), three remained in the ICU, two were still hospitalized but not in an ICU, and four had been discharged home.
The authors point out that the US cases of CVST with thrombocytopenia following the J&J vaccine have many similarities to those reported in Europe after the AstraZeneca vaccine, occurring primarily in women younger than 40 years and in patients without diagnosed thrombophilia. Both European and US patients had a median platelet nadir count of 19×103/µL and several also had non-CVST large-vessel thrombosis.
In the European cases of CVST with thrombocytopenia, 50% of patients died, compared with 25% of US patients.
However, in the initial European CVST reports, 88% of patients tested with functional platelet HIT antibody tests had positive results, compared with only 11% of the US cases. But the authors note that lack of standardization in functional platelet HIT antibody assays may lead to differences in results by different laboratories.
“It may be important to notify testing laboratories that post-vaccination TTS is being evaluated, so that testing methods can be adjusted if needed,” they say.
They conclude that these case reports suggest that the pathogenesis of TTS may be similar to autoimmune HIT, triggered by the formation of antibodies directed against PF4, a constituent of platelet alpha granules released during platelet activation. In contrast to classic HIT in which exogenous heparin triggers antibody formation, in autoimmune HIT, an endogenous polyanion triggers PF4 antibody formation.
They note that the precise mechanism of TTS in relation to COVID-19 vaccination has not yet been established. The Global Advisory Committee on Vaccine Safety has stated that a platform-specific mechanism related to adenovirus vector vaccines cannot be excluded. Both the J&J and AstraZeneca vaccines use an adenoviral vector, but they are different; J&J uses a human vector, while AstraZeneca uses a chimpanzee vector.
Créditos: Comité científico Covid